Preventing Left Ventricular Thrombus Formation: Another Reason to Use Very Low-Dose Rivaroxaban?
- PMID: 35367169
- DOI: 10.1016/j.jcin.2022.02.024
Preventing Left Ventricular Thrombus Formation: Another Reason to Use Very Low-Dose Rivaroxaban?
Keywords: acute myocardial infarction; direct oral anticoagulants; left ventricular thrombus.
Conflict of interest statement
Funding Support and Author Disclosures Dr Cavender has received research support to his institution for studies in which he is the principal investigator from Amgen, Boehringer Ingelheim, and CSL Behring; and has received consulting fees from Amgen, Bayer, Boehringer Ingelheim, Merck, and Novo-Nordisk. Dr Eubanks has reported that he has no relationships relevant to the contents of this paper to disclose.
Comment in
-
Prevention of Left Ventricle Thrombus Formation: Time for Action.JACC Cardiovasc Interv. 2022 Jun 27;15(12):1284-1285. doi: 10.1016/j.jcin.2022.04.039. JACC Cardiovasc Interv. 2022. PMID: 35738751 No abstract available.
Comment on
-
Prophylactic Rivaroxaban Therapy for Left Ventricular Thrombus After Anterior ST-Segment Elevation Myocardial Infarction.JACC Cardiovasc Interv. 2022 Apr 25;15(8):861-872. doi: 10.1016/j.jcin.2022.01.285. Epub 2022 Mar 30. JACC Cardiovasc Interv. 2022. PMID: 35367170 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
